Javier Cortes Selected Research

trastuzumab deruxtecan

1/2023	Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
1/2022	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
1/2020	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Javier Cortes Research Topics

Disease

106	Breast Neoplasms (Breast Cancer) 05/2024 - 03/2007
55	Neoplasms (Cancer) 12/2024 - 04/2007
25	Triple Negative Breast Neoplasms 05/2024 - 10/2014
10	Disease Progression 06/2023 - 03/2010
9	Pathologic Complete Response 08/2023 - 02/2015
9	Diarrhea 06/2023 - 12/2015
8	Neoplasm Metastasis (Metastasis) 10/2022 - 10/2014
7	Fatigue 12/2023 - 03/2011
7	Neutropenia 10/2022 - 03/2011
5	Nausea 12/2023 - 04/2012
4	Vomiting 12/2023 - 12/2015
3	Alopecia (Baldness) 12/2023 - 04/2012
3	Exanthema (Rash) 06/2023 - 10/2020
3	Brain Neoplasms (Brain Tumor) 01/2023 - 01/2003
3	Cardiotoxicity 09/2021 - 01/2009
3	Hypoxia (Hypoxemia) 06/2021 - 03/2017
3	Peripheral Nervous System Diseases (PNS Diseases) 03/2017 - 03/2011
2	Pneumonia (Pneumonitis) 07/2022 - 11/2015
2	Leukopenia 07/2022 - 05/2021
2	Sepsis (Septicemia) 01/2021 - 11/2015
2	Hypertension (High Blood Pressure) 01/2020 - 10/2014
2	Melanoma (Melanoma, Malignant) 01/2018 - 12/2015
2	Circulating Neoplastic Cells 01/2018 - 12/2015
2	Headache (Headaches) 10/2017 - 12/2015
2	Asthenia 10/2017 - 03/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2004 - 01/2003
1	Glioblastoma (Glioblastoma Multiforme) 01/2023

Drug/Important Bio-Agent (IBA)

26	Hormones (Hormone)IBA 05/2024 - 11/2009
22	ErbB Receptors (EGF Receptor)IBA 01/2024 - 11/2009
20	Biomarkers (Surrogate Marker)IBA 05/2024 - 07/2013
20	eribulin FDA Link 10/2022 - 04/2010
16	Trastuzumab (Herceptin)FDA Link 10/2023 - 04/2007
14	pembrolizumabIBA 05/2024 - 01/2020
12	Paclitaxel (Taxol)FDA LinkGeneric 08/2023 - 01/2003
12	AnthracyclinesIBA 11/2021 - 09/2010
11	human ERBB2 proteinIBA 01/2023 - 03/2010
10	taxaneIBA 01/2021 - 09/2010
9	Capecitabine (Xeloda)FDA Link 10/2022 - 09/2010
7	Cyclin-Dependent Kinase 4IBA 05/2024 - 09/2020
7	pertuzumabIBA 10/2022 - 03/2010
7	Gemcitabine FDA Link 10/2022 - 01/2003
7	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 12/2015
6	abemaciclibIBA 01/2024 - 11/2020
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 06/2007
5	sacituzumab govitecanIBA 05/2024 - 04/2020
5	Aromatase InhibitorsIBA 06/2023 - 01/2017
5	Monoclonal AntibodiesIBA 01/2023 - 04/2007
5	Estrogen ReceptorsIBA 01/2022 - 04/2015
5	Proteins (Proteins, Gene)FDA Link 10/2021 - 08/2012
5	Bevacizumab (Avastin)FDA Link 11/2020 - 04/2009
4	exemestane (Aromasin)FDA Link 12/2023 - 01/2017
4	Tamoxifen FDA LinkGeneric 10/2023 - 01/2021
4	Ado-Trastuzumab EmtansineIBA 01/2023 - 09/2012
4	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 05/2021
4	Vinorelbine (Navelbine)FDA LinkGeneric 10/2022 - 01/2003
4	130-nm albumin-bound paclitaxelIBA 12/2020 - 12/2015
4	Phosphotransferases (Kinase)IBA 01/2018 - 04/2007
3	Everolimus FDA Link 12/2023 - 10/2017
3	Fulvestrant (Faslodex)FDA Link 06/2023 - 04/2015
3	trastuzumab deruxtecanIBA 01/2023 - 01/2020
3	Antineoplastic Agents (Antineoplastics)IBA 01/2023 - 03/2011
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 12/2019
3	Lapatinib (GW572016)FDA Link 07/2022 - 04/2007
3	Taxoids (Taxanes)IBA 09/2021 - 03/2007
3	Phenobarbital (Luminal)FDA Link 11/2018 - 01/2018
3	Cell-Free Nucleic AcidsIBA 01/2018 - 07/2013
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 02/2014
3	Docetaxel (Taxotere)FDA Link 02/2017 - 03/2012
2	Epidermal Growth Factor (EGF)IBA 05/2024 - 12/2023
2	LigandsIBA 05/2024 - 01/2023
2	B7-H1 AntigenIBA 05/2024 - 01/2022
2	Immune Checkpoint InhibitorsIBA 01/2024 - 11/2020
2	ribociclibIBA 09/2023 - 12/2020
2	capivasertibIBA 06/2023 - 10/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2022 - 01/2019
2	AntigensIBA 10/2022 - 01/2019
2	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 01/2020
2	durvalumabIBA 12/2021 - 11/2020
2	liposomal doxorubicin (Doxil)FDA Link 09/2021 - 01/2009
2	enzalutamideIBA 05/2021 - 01/2018
2	Androgen Receptors (Androgen Receptor)IBA 05/2021 - 01/2018
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2020 - 04/2015
2	neratinibIBA 01/2020 - 12/2019
2	etirinotecan pegolIBA 01/2018 - 11/2015
2	ridaforolimusIBA 10/2017 - 01/2017
2	dalotuzumabIBA 10/2017 - 01/2017
2	nintedanibIBA 03/2017 - 03/2017
2	Analgesics (Analgesic Drugs)IBA 10/2014 - 04/2010
2	Cisplatin (Platino)FDA LinkGeneric 06/2004 - 01/2003
1	xentuzumabIBA 12/2023
1	Circulating Tumor DNAIBA 10/2023
1	margetuximabIBA 10/2023
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2023

Therapy/Procedure

55	Therapeutics 12/2024 - 01/2003
46	Drug Therapy (Chemotherapy) 05/2024 - 01/2003
9	Neoadjuvant Therapy 01/2023 - 11/2016
5	Radiotherapy 02/2024 - 01/2019
5	Immunotherapy 08/2023 - 01/2018
3	Aftercare (After-Treatment) 06/2023 - 10/2014
2	TP protocol 06/2004 - 01/2003